Team: Bios

Gary Patou, MD Managing Director

Prior to joining MPM in 2005, Dr. Patou as Executive Vice President and Chief Medical Officer of Oscient Pharmaceuticals, Inc., following its merger with GeneSoft Pharmaceuticals in 2004. As President of GeneSoft, Dr. Patou was instrumental in applying for and obtaining FDA approval of the Company's lead product, FACTIVE®. Before GeneSoft, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President & Director, Project and Portfolio Management, managing all of the company's pharmaceutical development projects including FACTIVE®, as well as FDA-approved products Avandia, Paxil and Augmentin. Dr. Patou also served as Director and Vice President of Anti-Infective Development where he managed the development of a broad line of anti-infective products, including oral, IV and topical antibiotics. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds medical and medical Ph.D. degrees from University College London.

Present Boards
Oscient Pharmaceuticals Corp. (NASDAQ:OSCI)
Xenon Pharmaceuticals, Inc.

Portfolio Assignments
Cerimon Pharmaceuticals, Inc., interim EVP and CMO; Founding Chairman and current member, Scientific Advisory Board
Peplin, Ltd. (ASX.PLI), interim Chief Medical Officer